Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07420283 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 465
- Enrollment target
- 20
- Study locations
NCT07420283 is a Phase 2 study of Opioid Use Disorder that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 465 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT07420283, a Phase 2 study of Opioid Use Disorder, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Buprenorphine
- DRUG Brenipatide
Study Locations (20)
Florida
- Bradenton Research Center, Inc. - Bradenton
- K2 Medical Research - Daytona Beach - Daytona Beach
- NextPhase Research Florida - Hollywood - Hollywood
- Accel Research Sites - Lakeland Clinical Research Unit - Lakeland
- Life Arc Research Centers - Miami - Miami
- Advanced Research for Health Improvement, LLC - Naples
- Innovative Research Institute - Port Charlotte - Port Charlotte
- Better Years Ahead Medical Center - Tampa
- Neuroscience Research Institute - West Palm Beach - West Palm Beach
California
- Ark Clinical Research - Fountain Valley - Fountain Valley
- Center on Substance Use and Health (CSUH) - San Francisco
- UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay - San Francisco
Alabama
- Parkway Medical Center - Birmingham
Arizona
- NoesisPharma - Phoenix - East Shea Boulevard - Phoenix
Arkansas
- Woodland International Research Group - Little Rock
Illinois
- Re:Cognition Health - Chicago - Chicago
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07420283
The ClinicalTrials.gov registry entry for NCT07420283 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (90% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07420283 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07420283 about?
NCT07420283 is a clinical study titled "A Study of Brenipatide in Participants With Opioid Use Disorder". The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 14...
What is the current status of trial NCT07420283?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 465 participants. The study started on 2026-02-13. Estimated completion is 2028-02.
What conditions does trial NCT07420283 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT07420283?
The interventions under investigation include: Placebo (DRUG), Buprenorphine (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07420283?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07420283 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.